Jazz Pharmaceuticals

Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023

Retrieved on: 
Wednesday, October 25, 2023
Jazz Pharmaceuticals, Interest, Nightclub, Broadcasting

DUBLIN, Oct. 25, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 third quarter financial results on Wednesday, November 8, 2023, after the close of the U.S. financial markets.

Key Points: 
  • DUBLIN, Oct. 25, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 third quarter financial results on Wednesday, November 8, 2023, after the close of the U.S. financial markets.
  • ET / 9:30 p.m. GMT to discuss 2023 third quarter financial results and provide a business and financial update.
  • Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations .
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Real-World, Evidence-Based Approaches for Individualized Treatment in Adults w

Retrieved on: 
Monday, October 23, 2023
MB, Jazz Pharmaceuticals, Sodium, Mercury (element), Literature, Blood pressure, Congress, Narcolepsy, MD, Observational study, American Heart Association, Cataplexy, Disease, Idiopathic hypersomnia, Systematic review, Gamma-Hydroxybutyric acid, Sleep, Magnesium, American Heart, Risk, Somnolence, Colorado Ultraviolet Transit Experiment, Patient, Calcium, MRCPCH, Potassium, Medicine, Diagnosis, Cardiovascular disease, Mercury, Salt, Pharmaceutical industry, Person, Sodium oxybate, Xywav

DUBLIN, Oct. 23, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new data that examine the comorbid risk of cardiovascular disease in patients with narcolepsy and idiopathic hypersomnia as well as the effect of sodium intake on cardiovascular health. The Company will also present results from the real-world TENOR study on individualized dosing regimens for adults with type 1 or type 2 narcolepsy transitioning to low-sodium Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution from high-sodium Xyrem® (sodium oxybate) oral solution. The study will be presented today at the World Sleep 2023 Congress in an oral session on evidence-based approaches for optimizing pharmacologic treatment for narcolepsy.

Key Points: 
  • The Company will also present results from the real-world TENOR study on individualized dosing regimens for adults with type 1 or type 2 narcolepsy transitioning to low-sodium Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution from high-sodium Xyrem® (sodium oxybate) oral solution.
  • The study will be presented today at the World Sleep 2023 Congress in an oral session on evidence-based approaches for optimizing pharmacologic treatment for narcolepsy.
  • "Real-world data regarding individualized dosing regimens for the treatment of narcolepsy are limited.
  • The TENOR study was a patient-centric, prospective, observational study of U.S. adults with type 1 or type 2 narcolepsy.

BioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023

Retrieved on: 
Thursday, October 19, 2023
BLFS, Acquisition, CGT, Jazz Pharmaceuticals, Growth, Lead, Takeda Pharmaceutical Company, Cryobiology, Management, Refrigerator

BOTHELL, Wash., Oct. 19, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced Roderick de Greef has been appointed as Chairman of the Board of Directors and Chief Executive Officer replacing Michael Rice who is retiring after a seventeen year tenure, effective immediately. Rice has agreed to consult for the Company until March 31, 2024, to support a smooth transition.

Key Points: 
  • The Company is reporting preliminary, unaudited revenue for the third quarter of 2023 of approximately $33.3 million.
  • Preliminary revenue for Storage and Storage Services, and Freezers and Thaw Systems platforms was $6.6 million and $13.4 million, respectively.
  • The preliminary revenue set forth above are unaudited and remain subject to ongoing review and adjustment.
  • The Company will report complete results on its third quarter 2023 earnings call currently scheduled for November 9, 2023.

Jazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023

Retrieved on: 
Wednesday, October 18, 2023
Jazz Pharmaceuticals, Stroke, Splenic infarction, Sleep disorder, Sodium, MSCE, Literature, Blood pressure, Sleep medicine, Congress, Narcolepsy, Prevalence, Idiopathic hypersomnia, Systematic review, Research, Sleep, Magnesium, Sodium oxybate, SEGUE, Abstract, Cancer, CV, Patient, Calcium, Potassium, Heart failure, Medicine, Cardiovascular disease, Nightclub, Pharmaceutical industry, MD

DUBLIN, Oct. 18, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present 14 abstracts from across its sleep medicine portfolio, including two oral presentations, at the 17th annual World Sleep 2023 Congress, held October 20-25 in Rio de Janeiro, Brazil.

Key Points: 
  • DUBLIN, Oct. 18, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present 14 abstracts from across its sleep medicine portfolio, including two oral presentations, at the 17th annual World Sleep 2023 Congress, held October 20-25 in Rio de Janeiro, Brazil.
  • The oral presentations include findings from the real-world TENOR study, which demonstrated individualized dosing strategies for twice-nightly oxybate treatment in narcolepsy.
  • The World Sleep 2023 schedule is available online and outlines all abstracts, posters and oral presentations slated to be shared at the congress.
  • All abstracts are published in a supplemental issue of Sleep Medicine, the official journal of World Sleep Society, two months after the event.

Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer

Retrieved on: 
Monday, October 16, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Genentech, LLP, Drug development, Abstract, Harvard University, Pfizer, Data management, Drug, Pharmacyclics, Arena Pharmaceuticals, Therapy, SMMT, Quality of life, Lasso, PwC, Knowledge, Amgen, Biogen, AbbVie, Athenahealth, CFO, Stonehill College, Faculty, Risk, Jazz Pharmaceuticals, University, Cancer, Jazz, Trust, Nektar, Immunotherapy, CMO, Biostatistics, Information technology, Alnylam Pharmaceuticals, MD Anderson Cancer Center, Public health, Regulatory affairs, Nektar Therapeutics, Sale, Senior, Doctor of Philosophy, Licensed practical nurse, ARIAD Pharmaceuticals, Growth, Hematology, Patient, Management, Nursing, Pharmacovigilance, Robert Maki

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Manmeet S. Soni has been appointed as the Company’s Chief Operating Officer, effective immediately.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Manmeet S. Soni has been appointed as the Company’s Chief Operating Officer, effective immediately.
  • “Manmeet Soni has few peers in this industry, and his track record speaks for itself,” stated Dr. Maky Zanganeh, Chief Executive Officer and President of Summit.
  • “Leveraging his leadership and wisdom on a daily basis is a powerful addition to the already formidable Team Summit.
  • I am grateful for the trust he has displayed in Maky, me, and our team in joining our mission full-time.”
    Mr. Soni has over 20 years of financial and operational leadership experience and joins Summit from Reata Pharmaceuticals, Inc., where he was President, Chief Operating Officer, & Chief Financial Officer.

Jazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023

Retrieved on: 
Monday, October 16, 2023
Congress, Cancer, Abstract, ORR, Tislelizumab, SCLC, BeiGene, Biliary tract, Jazz Pharmaceuticals, Safety, Dor, Patient, Oncology, ESMO, Lurbinectedin, Quality of life (healthcare), Carcinoma, Protein, PFS, European Society for Medical Oncology, Progression-free survival, HER2, Research, BTC, Nightclub, Pharmaceutical industry

DUBLIN, Oct. 16, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with partners, will present six abstracts including data from trials of bispecific antibody zanidatamab and Zepzelca® (lurbinectedin), as well as the study design for a Phase 1 trial of the pan-RAF inhibitor JZP815, at the European Society for Medical Oncology (ESMO) Congress 2023, taking place in Madrid, Spain, from October 20-24, 2023.

Key Points: 
  • DUBLIN, Oct. 16, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with partners, will present six abstracts including data from trials of bispecific antibody zanidatamab and Zepzelca® (lurbinectedin), as well as the study design for a Phase 1 trial of the pan-RAF inhibitor JZP815, at the European Society for Medical Oncology (ESMO) Congress 2023, taking place in Madrid, Spain, from October 20-24, 2023.
  • "The compelling data being presented at ESMO by Jazz and partners, in particular for zanidatamab in biliary tract and gastric cancers, demonstrate the clinical potential of our solid tumor oncology development programs to raise the standard of care for some of the most difficult-to-treat cancers," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals.
  • "Through our expanding research in solid tumors – including targeted therapies and immuno-oncology – Jazz is advancing novel investigational therapies that target specific proteins like HER2 and important signaling pathways such as the RAS-RAF-MAPK pathway."
  • A poster presentation featuring progression-free survival (PFS) and duration of response (DoR) results from a Phase 1b/2 study of zanidatamab plus chemotherapy in combination with tislelizumab for the first-line treatment of HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC).

Peptone Expands Leadership Team with Key Executive Hires

Retrieved on: 
Thursday, September 28, 2023
University of Oxford, DNA, Laboratory, Specialization, Drug development, University, Therapy, Senior, Intrinsically disordered proteins, Chiron Corporation, Drug discovery, CSO, Head, Abbott Laboratories, Nuffield Department of Population Health, Gritstone bio, Inflammation, Antibody, Doctor of Philosophy, AstraZeneca, Drug design, Internally displaced person, Messenger, McKinsey & Company, Neuroscience, Cryogenic electron microscopy, Protein, MD, Biophysics, Chairperson, Jazz Pharmaceuticals, Biology, Growth, Imperial College London, Rucaparib, Exosome, DNA methylation, Research, Clovis Oncology, Health, A-DNA, SVP, PARP, Somerville College, Oxford, Disease, Management, Pharmaceutical industry, Medicine, Peptide, Immunology

LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors. Patrik Foerch, PhD, has been appointed Chief Scientific Officer; David Lowe, PhD, joins as Senior Vice President of Protein Therapeutics; and Benjamin Owens, PhD, previously Chief Strategy Officer, has transitioned to the role of Chief Business Officer and will join Peptone's Board of Directors as Executive Director. Andrew Allen, MD, PhD, co-founder, President and CEO of Gritstone bio, has been appointed Board Chair.

Key Points: 
  • LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors.
  • "I'm excited to join this incredible team to chart new territory with potential to open therapeutic opportunities across a broad range of diseases."
  • Prior to joining Peptone, he served as Vice President of Research at Evox Therapeutics, a company focused on the development of exosomes as therapeutics.
  • He has also held clinical development leadership positions at Chiron Corporation and Abbott Laboratories and worked at McKinsey & Company.

Peptone Expands Leadership Team with Key Executive Hires

Retrieved on: 
Thursday, September 28, 2023
University of Oxford, DNA, Laboratory, Specialization, Drug development, University, Therapy, Senior, Intrinsically disordered proteins, Chiron Corporation, Drug discovery, CSO, Head, Abbott Laboratories, Nuffield Department of Population Health, Gritstone bio, Inflammation, Antibody, Doctor of Philosophy, AstraZeneca, Drug design, Internally displaced person, Messenger, McKinsey & Company, Neuroscience, Cryogenic electron microscopy, Protein, MD, Biophysics, Chairperson, Jazz Pharmaceuticals, Biology, Growth, Imperial College London, Rucaparib, Exosome, DNA methylation, Research, Clovis Oncology, Health, A-DNA, SVP, PARP, Somerville College, Oxford, Disease, Management, Pharmaceutical industry, Medicine, Peptide, Immunology

LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors. Patrik Foerch, PhD, has been appointed Chief Scientific Officer; David Lowe, PhD, joins as Senior Vice President of Protein Therapeutics; and Benjamin Owens, PhD, previously Chief Strategy Officer, has transitioned to the role of Chief Business Officer and will join Peptone's Board of Directors as Executive Director. Andrew Allen, MD, PhD, co-founder, President and CEO of Gritstone bio, has been appointed Board Chair.

Key Points: 
  • LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors.
  • "I'm excited to join this incredible team to chart new territory with potential to open therapeutic opportunities across a broad range of diseases."
  • Prior to joining Peptone, he served as Vice President of Research at Evox Therapeutics, a company focused on the development of exosomes as therapeutics.
  • He has also held clinical development leadership positions at Chiron Corporation and Abbott Laboratories and worked at McKinsey & Company.

Black Health Matters Summit & Expo Returns to Los Angeles

Retrieved on: 
Tuesday, September 26, 2023
Saint Anne, Sarcoidosis, Radio personality, Carcinoma, Asthma, Diabetes, Clinical trial, Regeneron Pharmaceuticals, The Original Kings of Comedy, Guru, Janssen, D. L. Hughley, Bristol Myers Squibb, FREE, Doctor of Philosophy, NAACP Image Awards, Hypertension, Dermatology, Blood, MD, Anemia, Lunch, Conditional sentence, Sanofi, Jazz Pharmaceuticals, American Cancer Society, ATyr Pharma, Health, Emmy Awards, Summit, Mental health, Radio, Conference, BHM, Pharmaceutical industry, Vertex, Genentech

NEW YORK, Sept. 26, 2023 /PRNewswire/ -- After a triumphant debut in Los Angeles in 2022, Black Health Matters (BHM) is once again bringing its nationally acclaimed health summit series to the west coast. On Saturday, October 7, 2023, the Black Health Matters Fall Health Summit & Expo will be held at St. Anne's Family Services Conference Center, 155 N. Occidental Blvd., Los Angeles, CA 90026, from 8:30 AM to 3:30 PM PST/11:30 AM to 6:30 PM EST. The Summit is FREE, open to the community, and offers attendees the option of attending either in-person or virtually. This event is like none other, connecting medical clinicians, authorities on health, wellness and chronic illness, patient advocates and celebrity guests who are eager to bring health awareness to the public. Attendees will be treated to stimulating and informative panel discussions, presentations, energizing fitness sessions, and free health screenings and immunizations. Complimentary breakfast and lunch will be offered, and FREE giveaways and prizes will be distributed throughout the day. To register go to www.bhmfallsummit2023.com for in-person or virtual attendance.

Key Points: 
  • NEW YORK, Sept. 26, 2023 /PRNewswire/ -- After a triumphant debut in Los Angeles in 2022, Black Health Matters (BHM) is once again bringing its nationally acclaimed health summit series to the west coast.
  • On Saturday, October 7, 2023, the Black Health Matters Fall Health Summit & Expo will be held at St. Anne's Family Services Conference Center, 155 N. Occidental Blvd., Los Angeles, CA 90026, from 8:30 AM to 3:30 PM PST/11:30 AM to 6:30 PM EST.
  • "We are thrilled that Black Hollywood is rallying behind us to help us inspire, inform, uplift and empower people by linking leading health experts and advocates with attendees," says Roslyn Young-Daniels, founder, and president of Black Health Matters.
  • Everyone who attends the Black Health Matters Summit & Expo will be able benefit from free on-site health screenings and testing, such as mammograms, diabetes, hypertension, heart function, anemia, blood glucose, blood hemoglobin, adequate oxygenation, plus more to be announced.

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Retrieved on: 
Friday, September 22, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Hypersensitivity, Neutropenia, Contraindication, Maintenance, Lymphocyte, Acute leukemia, Pancreatitis, Febrile neutropenia, IV, Civil service commission, MWF, Diarrhea, ALL, Acute lymphoblastic leukemia, IM, COG, Appetite, Abdominal pain, European Commission, NSAA, Sepsis, LBL, Vomiting, Patient, European, Anemia, Nausea, Headache, EC, Jazz Pharmaceuticals, Thrombocytopenia, Safety, Fatigue, Vaccine, Ligand Pharmaceuticals, Fever

“We congratulate our partner Jazz on its receipt of approval for Enrylaze® from the European Commission, expanding the market opportunity for one of our key commercial-stage products,” said Todd Davis, CEO of Ligand Pharmaceuticals.

Key Points: 
  • “We congratulate our partner Jazz on its receipt of approval for Enrylaze® from the European Commission, expanding the market opportunity for one of our key commercial-stage products,” said Todd Davis, CEO of Ligand Pharmaceuticals.
  • The determination of efficacy was based on demonstration of the achievement and maintenance of nadir serum asparaginase activity (NSAA) levels ≥ 0.1 U/mL.
  • Overall, the safety profile of JZP458 was consistent with the reported safety information for patients with ALL/LBL receiving asparaginase with combination chemotherapy.
  • The European Commission approval extends to all European Union Member states, as well as Iceland, Norway, and Liechtenstein.